Much of the excitement over Gilead is due to the balm, so to speak, that the company discovered for Covid-19: A repurposed antiviral called remdesivir that the Food and Drug Administration authorized to treat Covid-19 in May.On July 21, Gilead announced it had acquired 49.9% of a cancer immunotherapy firm called Tizona Therapeutics for $300 million, and that it has the rights to buy the rest of the company for another $1.3 billion.